[1]
|
R. E. Heikkila and P. K. Sonsalla, “The MPTP Treated Mouse as a Model of Parkinsonism: How Good Is It?” Neurochemistry International, Vol. 20, 1992, pp. 299-303.
doi:10.1016/0197-0186(92)90256-Q
|
[2]
|
P. Grandjean and P. J. Landrigan, “Developmental Neurotoxicity of Industrial Chemicals.” Lancet, Vol. 368, No. 9553, 2006, pp. 2167-2178.
doi:10.1016/S0140-6736(06)69665-7
|
[3]
|
H. R. Andersen, J. B. Nielsen and P. Grandjean, “Toxicologic Evidence of Developmental Neurotoxicity of Environmental Chemicals,” Toxicology, Vol. 144, No. 1-3, 2000, pp. 121-127. doi:10.1016/S0300-483X(99)00198-5
|
[4]
|
L. G. Costa. M. Aschner, A. Vitalone, T. Syversen and O. P. Soldin, “Developmental Neuropathology of Environmental Agents,” Annual Review of Pharmacology and Toxicology, Vol. 44, No. 1, 2004, pp. 87-110.
doi:10.1146/annurev.pharmtox.44.101802.121424
|
[5]
|
Z. Ling, D. A, Gayle, S.Y. Ma, J. W. Lipton, C. W. Tong, J. S. Hong and P. M. Carvey, “In Utero Bacterial Endotoxin Exposure Causes Loss of Tyrosine Hydroxylase Neurons in the Postnatal Rat Midbrain,” Movement Disorders, Vol. 17, No. 1, 2002, pp. 116-124.
doi:10.1002/mds.10078
|
[6]
|
D. B. Calne and J. W. Langston, “Etiology of Parkinson’s Disease,” Lancet, Vol. 322, No. 8365, 1983, pp. 1457- 1459. doi:10.1016/S0140-6736(83)90802-4
|
[7]
|
P. H. V. Jenner, A. Shapira and C. D. Marsden, “New Insight in to the Cause of Parkinson’s Disease”. Neurology, Vol. 42, No. 12, 1992, pp. 2241-2250.
doi:10.1212/WNL.42.12.2241
|
[8]
|
K. Aoyama, M. Matsubara, Y. Kondo, M. Murakawa, K. Suno and S. Yamaguchi, “N-Methylation Ability for Azaheterocyclic Amines in Higher in Parkinson’s Disease: Nicotinamide Loading Test,” Journal of Neural Transmission, Vol. 107, No. 8-9, 2000, pp. 985-995.
doi:10.1007/s007020070047
|
[9]
|
D. A. Di Monte, “The Environment and Parkinson’s Disease: Is the Nigrostriatal System Preferentially Targeted by Neurotoxins,” The Lancet Neurology, Vol. 2, No. 9, 2003, pp. 531-538.
|
[10]
|
J. L. Kennedy, L. A. Farrer, N. C. Andreason, R. Mayeux and P. St. George Hyslop, “The Genetics of Adult-Onset Neuropsychiatric Disease: Complexities and Conundra?” Science, Vol. 302, No. 5646, 2003, pp. 822-826.
doi:10.1126/science.1092132
|
[11]
|
G. Anderson, A. R. Noorian, G. Taylor, M. Anitha, D. Bernhrd, S. Srinivasan and J. G. Greene, “Loss of Enteric Dopaminergic Neurons and Associated Changes in Colon Mortility in an MPTP Mouse Model of Parkinson’s Disease,” Experimental Neurology, Vol. 207, No. 1, 2007, pp. 4-12. doi:10.1016/j.expneurol.2007.05.010
|
[12]
|
G. Natale, O. Kastsiushenka, F. Fulceri, S. Ruggieri, A. Paparelli and F. Fornai, “MPTP-Induced Parkinsonism Extends to a Subclass of TH-Positive Neurons in the Gut,” Brain Research, Vol. 1355, No. 8, 2010, pp. 195-206.
doi:10.1016/j.brainres.2010.07.076
|
[13]
|
A. G. Kanthasamy, M. Kitazawa, A. Kanthasamy and V. Anantharaman, “Dieldrin-Induced Neuro Toxicity: Relevance to Parkinson’s Disease Pathogenesis,” Neurotoxicology, Vol. 26, No. 4, 2005, pp. 701-719.
|
[14]
|
S. A. Lloyd, C. Faherty and R. J. Smeyne, “Adult and in Utero Exposure to Cocaine Alters Sensitivity to the Parkinsonian Toxin 1-Methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine,” Neuroscience, Vol. 137, No. 3, 2006, pp. 905-913.
doi:10.1016/j.neuroscience.2005.09.035
|
[15]
|
C. G. Charlton, “A Parallel Relationship between Parkinson’s Disease and Excess of S Adenosylmethionine dependent Biological Methylation in the Brain,” Basic, Clinical and Therapeutic Aspects of Alzheimer’s and Parkinson’s Disease, Vol. 1, Cpt. 65, 1990, pp. 333-339.
|
[16]
|
C. G. Charlton and B. Crowell, “Parkinson’s Disease like Effects of S Adenosyl methionine: Effects of L dopa,” Pharmacology Biochemistry and Behavior, Vol. 43, No. 2, 1992, pp. 423 431. doi:10.1016/0091-3057(92)90172-C
|
[17]
|
L. Axelrod and J. Tomchick. “Enzymatic-O-methylation of Epinephrine and Other Catechols,” Journal of Biological Chemistry, Vol. 233, No. 3, 1958, pp. 702-705.
|
[18]
|
C. G. Charlton and B. Crowell, “Striatal Dopamine Depletion, Tremors and Hypokinesia Following the Intracranial Injection of S Adenosylmethionine,” Molecular and Chemical Neuropathology, Vol. 26, No. 3, 1995, pp. 269- 284. doi:10.1007/BF02815143
|
[19]
|
C. G. Charlton and J. Mack, “Substantia Nigra Degeneration and Tyrosine Hydroxylase Depletion Caused by Excess S Adenosylmethionine in the Rat Brain: Support for an Excess Methylation Hypothesis for Parkinsonism,” Molecular Neurobiology, Vol. 9, No. 1-3, 1994, pp. 149 161.
doi:10.1007/BF02816115
|
[20]
|
G. Muthian, V. Mackey and C. G. Charlton, “Modeling a Sensitization Stage and a Precipitation Stage for Parkinson’s Disease Using Prenatal and Postnatal 1-Methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration,” Neuroscience, Vol. 169, No. 3, 2010, pp. 1085-1093. doi:10.1016/j.neuroscience.2010.04.080
|
[21]
|
C. G. Charlton, “Depletion of Nigrostriatal and Forebrain Tyrosine Hydroxylase by S-Adenosylmethionine: A Model That May Explain the Occurrence of Depression in Parkinson’ Disease,” Life Sciences, Vol. 61, No. 5, 1997, pp. 495-502. doi:10.1016/S0024-3205(97)00409-8
|